Form Type: 4

SEC EDGAR Link
Accession Number:0000899243-21-018274
Date:2021-05-01
Issuer: CLOVIS ONCOLOGY, INC. (CLVS)
Original Submission Date:

Reporting Person:

GROSS PAUL EDWARD
C/O CLOVIS ONCOLOGY, INC.
5500 FLATIRON PARKWAY, SUITE 100 BOULDER, CO 80301

Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
Title of SecurityTransaction Date2a. Deemed Execution Date Transaction CodeSharesAcquired or DisposedPrice per share 5. Amount of Securities Beneficially Owned Following Reported Transaction 6. Ownership Form Direct or IndirectNature of Indirect Ownership
COMMON STOCK 2021-05-01 M 2,556 a $0.00 46,077 direct
COMMON STOCK 2021-05-04 S 1,207 d $5.54 44,870 direct
COMMON STOCK 2021-05-01 M 4,625 a $0.00 49,495 direct
COMMON STOCK 2021-05-04 S 2,183 d $5.54 47,312 direct
COMMON STOCK 2021-05-01 M 3,067 a $0.00 50,379 direct
COMMON STOCK 2021-05-04 S 1,448 d $5.54 48,931 direct
Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, convertible securities
Title of Derivative Security Conversion or Exercise Price of Derivative Security Transaction Date Deemed Execution Date Transaction Code Number of Derivative Securities Acquired (A) or Disposed of (D) Date ExercisableExpiration Date Title and Amount of Securities Underlying Derivative Security Price of Derivative Security Number of derivative Securities Beneficially Owned Following Reported Transaction(s) Ownership Form: Direct (D) or Indirect (I) Nature of Indirect Beneficial Ownership
RESTRICTED STOCK UNITS 0.0 2021-05-01 deemed execution date M 5,623 (d) common stock 5,623 $0.00 39,367 direct
RESTRICTED STOCK UNITS 0.0 2021-05-01 deemed execution date M 4,625 (d) common stock 4,625 $0.00 50,875 direct
Footnotes
IDfootnote
f1 each restricted stock unit represents the right to receive one share of common stock.
f2 represents the shares automatically sold by the reporting person pursuant to an election to satisfy tax withholding obligations in connection with the vesting of the restricted stock units listed in table ii. this sale does not represent a discretionary trade by the reporting person.
f3 on february 1, 2019, the reporting person was granted 89,982 restricted stock units. 25% of such restricted stock units vested on february 1, 2020, and the remainder vests in substantially equal installments over the 12 quarters immediately following such date.
f4 on january 31, 2020, the reporting person was granted 74,000 restricted stock units. 25% of such restricted stock units vested on february 1, 2021, and the remainder vests in substantially equal installments over the 12 quarters immediately following such date.
f5 this transaction was executed in multiple trades at prices ranging from $5.53 to $5.56. the price reported above reflects the weighted average sale price. the reporting person hereby undertakes to provide upon request to the sec staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.

Elevate your investments